Episode 34 – Travis Young: Finding a cure for cancer with novel immunotherapies

Dr. Travis Young is the Vice President of Biologics at Calibr, the drug discovery and development division of Scripps Research. Travis and the team have created a new type of immunotherapy called “switchable” chimeric antigen receptor (CAR) T-cell therapy, which is already delivering precise and powerful therapies to patients with the most difficult to treat cancers. Listen as we talk about reengineering an individual’s immune T cells, promising clinical trials in leukemia and lymphoma patients, and using similar approaches to treat autoimmune diseases. Show notes: Episode transcript: https://www.scripps.edu/_files/images/2022_images/podcast-images/Travis-Young-transcript.pdf Travis and his colleagues discuss ongoing therapies being developed at Calibr during the Front Row lecture series https://www.youtube.com/watch?v=WRzQniqUlHo&t=2625s Preliminary results of switchable CAR-T cells in lymphoma patients https://www.scripps.edu/news-and-events/press-room/2021/20211208-calibr-announces-clinical-data-car-t-cells.html Tweet: @CARTCellTherapy Explore the Scripps Research Magazine https://magazine.scripps.edu/ Subscribe to receive our monthly e-newsletter https://signup.e2ma.net/signup/1879047/1890109/ @scrippsresearch on Twitter